Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE OncoPlex Diagnostics
ROCKVILLE, Md., May 15, 2014 /PRNewswire/ -- OncoPlex Diagnostics, a niche molecular diagnostics company providing clinical proteomics for personalized patient care, has been granted a patent by the European Patent Office (EU1601450) for its core technology, the Liquid Tissue® process. OncoPlex Diagnostics now has multiple issued patents covering the Liquid Tissue process in the United States and other countries worldwide.
Liquid Tissue MS protein preparation allows OncoPlex Diagnostics to process formalin fixed, paraffin embedded (FFPE) tissue for accurate quantitation of multiple peptides by mass spectrometry. Historically, the standard method for proteomic analysis of FFPE tissue is immunohistochemistry (IHC) which suffers from being semi-quantitative, lacking specificity, and generating false-positives. The Liquid Tissue protocol and associated Liquid Tissue -SRM assays make it possible to precisely and reproducibly quantitate multiple proteins simultaneously (>20) in a single assay directly in patient-derived clinical FFPE tissue to improve cancer therapy decisions.
"Having patent protection for our intellectual property in Europe gives OncoPlex Diagnostics the ability to expand our reach into this very important market," said Dr. Jon Burrows, CEO. "Adoption of our clinical tests is expanding across the United States and there is great interest in these tests worldwide." OncoPlexDx's Liquid Tissue technology platform is being used to provide actionable information for clinical decisions directly to oncologists to personalize care for oncology patients. The ChemoPlex™ multiplexed assay measures proteins concurrently such as hENT1, RRM1, SPARC and TOPOIIA to guide treatment decisions for standard chemotherapy as well as quantitating biomarkers for targeted therapies such as Androgen Receptor, EGFR, HER2, HER3, MET, and PD-L1.
About OncoPlex Diagnostics: www.oncoplexdx.com
OncoPlex Diagnostics operates a CAP-accredited, CLIA-certified molecular diagnostics laboratory in Rockville, MD. OncoPlex Diagnostics has an important single focus: providing the most comprehensive characterization of patient derived tumor tissue for enhanced cancer treatment decisions. The company's proprietary multiplexed method is one of the most sensitive and specific detection tools available in the clinical laboratory today.
©2012 PR Newswire. All Rights Reserved.